2-Chloro-5-Hydroxymethylthiazole Hydrochloride

What Drives the Sensitivity of Thiamethoxam Coupling to Residual Formamide in Recycled DMF Streams?

The synthetic route to thiamethoxam technical concentrate via 2-chloro-5-hydroxymethylthiazole hydrochloride pivots on a nucleophilic displacement between the chlorothiazole carbinol and the preformed oxadiazine moiety 3-methyl-4-nitroimino-tetrahydro-1,3,5-oxadiazine. The reaction is executed under anhydrous alkaline conditions in dimethylformamide (DMF) at 78–82°C for a duration of 14–18 hours, using milled potassium carbonate (K₂CO₃, 325 mesh) at a loading of 2.2 molar equivalents relative to the oxadiazine. The critical-to-quality attribute dictating batch acceptance is the sum of des-chloro and dehydroxy-methyl impurities, which surge when recycled DMF retains >0.15% w/w formamide arising from thermal decomposition of the solvent. A wiped-film evaporator operating at 12 mbar and 115°C jacket temperature is deployed to recover DMF with a formamide threshold below 0.06%. The molar ratio of 2-chloro-5-hydroxymethylthiazole (freshly liberated from its hydrochloride salt using 45% w/w sodium hydroxide at 5–10°C) to oxadiazine is maintained at 1.07:1 to offset chlorothiazole ring losses to hydrolysis; post-reaction HPLC analysis (column: C18, 5 µm, 250×4.6 mm; mobile phase: acetonitrile/water with 0.1% trifluoroacetic acid) quantifies the target peak at retention time 8.2 min. Once conversion exceeds 97.8%, the crude mass is quenched into demineralized water at 2°C, and the precipitated solid is recrystallized from 70% v/v methanol-water to yield thiamethoxam with a polymorphic purity suitable for downstream formulation. Regulatory compliance in this segment draws on OECD Test Guideline 503 for residue chemistry, CIPAC methods MT 168.2 for active ingredient identification, and the tolerances established in Regulation (EC) 396/2005 for maximum residue limits. The resulting technical material—typically ≥98.5% purity—is subsequently converted into water-dispersible granules (WG) via a fluidized-bed agglomeration process using a starch-lactose binder system at an inlet air temperature of 68–72°C, or suspension concentrates (SC) with a viscosity plateau of 450–800 mPa·s stabilized by alkylnaphthalene sulfonate condensates.

In the corresponding clothianidin production stream, the same hydrochloride building block is deployed without isolation of the free base, and the downstream process behaves differently with respect to entrainer selection and residual water control—a comparison of the two neonicotinoid routes reveals distinct impurity fingerprints and has been consolidated in the following operational matrix.

Industrial conversion of the hydrochloride salt to clothianidin begins with a low-temperature neutralization in a glass-lined or Hastelloy C-22 reactor due to the corrosive load of the liberated hydrogen chloride. A 20% w/w aqueous sodium carbonate solution is introduced over 45–60 minutes while maintaining the inner coil temperature at 8–12°C. Once the aqueous phase reaches pH 7.8–8.1, agitation is halted and the lower chlorothiazole oil layer is separated, washed with cold brine (5°C), and transferred to a second vessel containing 1-methyl-2-nitroguanidine suspended in toluene. A Dean-Stark trap is fitted, and the batch is heated to vigorous reflux at 110–112°C. Water removal is monitored by a turbidity probe in the return leg; the reaction is judged complete when the rate of water evolution falls below 0.05 mL/h per kg reaction mass. The mixture is then cooled to –5°C over 6 hours, and the crystalline clothianidin is filtered through a centrifuge with polytetrafluoroethylene (PTFE) filter cloth, rinsed with chilled toluene, and dried in a conical vacuum dryer at 45°C and 25 mbar for 14 hours. Residual solvent content is verified by headspace gas chromatography to remain below 500 ppm for toluene. This sequence delivers a polymorphically consistent orthorhombic crystal habit that resists caking during subsequent formulation into suspension concentrates. Finished formulation types include flowable concentrates for seed treatment (FS) with a typical particle size D90 of 3.5 µm achieved on a bead mill with yttria-stabilized zirconia beads 0.4–0.6 mm, and water-dispersible granules (WG) produced on a twin-screw extruder with an L/D ratio of 32:1 at a die temperature of 48–52°C. The entire operation conforms to FAO Specification 757/TC (2020), analytical methods listed in CIPAC Handbook N, and the batch-release criteria of EPA 40 CFR Part 158.

The Copper(I)-Catalyzed Ammonolysis Protocol for 2-Aminothiazole Key Starting Materials Under GMP Annex 6

For applications within the pharmaceutical supply chain where the 2-chloro substituent must be converted into a primary amine to serve as a late-stage diversification handle, a catalytic ammonolysis step transforms 2-chloro-5-hydroxymethylthiazole hydrochloride into 2-amino-5-hydroxymethylthiazole. The reaction is conducted in a pressure-rated Hastelloy autoclave with a rushton turbine agitator, using 28% w/w aqueous ammonia at a molar ratio of 10.0–12.5 equivalents relative to the chlorothiazole, and copper(I) chloride (CuCl) at a loading of 1.5–2.0 mol% as the catalyst. The slurry is brought to 125°C under an initial nitrogen overpressure of 3 bar and held for 20–24 hours; during this period the internal pressure rises to approximately 8 bar due to ammonium chloride formation. End-of-reaction is determined by quenching an aliquot into phosphate buffer (pH 7.0) and analyzing by UPLC with a charged-surface hybrid (CSH) C18 column, confirming residual chlorothiazole below 0.15 area%. Upon cooling to 40°C, the crude mixture is filtered through a 0.2 µm polypropylene filter cartridge and concentrated on a thin-film evaporator at 60°C and 85 mbar to remove excess ammonia. The resulting brown oil is treated with activated carbon (Norit CN1, 3% w/w) and then acidified with 37% hydrochloric acid to precipitate the 2-aminothiazole hydrochloride, which is recrystallized from isopropanol/water (85:15 v/v) to a purity exceeding 99.5 area% by HPLC at 254 nm. This intermediate conforms to ICH Q7 Good Manufacturing Practice for active pharmaceutical ingredients and is routinely released against a specification monograph aligned with USP general chapter <1086>. In a validated generic drug synthesis, this aminothiazole core is reductively coupled with a protected L-tert-leucine aldehyde to construct the hydroxyethylamine isostere characteristic of certain HIV protease inhibitors bearing a 2-aminothiazole P2 ligand. Here the incorporation level is stoichiometric: 1.00–1.02 equivalents of the aldehyde component per equivalent of aminothiazole, with the condensation performed in tetrahydrofuran at –15 to –10°C using sodium triacetoxyborohydride (1.3 eq). The downstream production step chains into a hydrochloride salt deprotection with anhydrous HCl in dioxane (4 N, 2.5 eq) and finally into a peptide coupling stage that delivers the drug substance in its acetate salt form.

Antibody-drug conjugate development employing a cathepsin-B cleavable valine-citrulline dipeptide linker frequently incorporates a para-aminobenzyl-thiazole self-immolative spacer derived from 2-amino-5-hydroxymethylthiazole. Here the hydroxymethyl group is activated to a para-nitrophenyl carbonate ester, allowing attachment to the linker’s benzylamine terminus. In a Schlenk flask purged with dry nitrogen, the aminothiazole hydrochloride is dissolved in anhydrous N,N-dimethylacetamide containing 2.5 equivalents of triethylamine, cooled to 0°C, and treated with a 1.05:1 molar ratio of bis-(para-nitrophenyl) carbonate relative to the thiazole. The mixture is stirred for 4 hours at 5°C, then quenched with 5% w/v citric acid and extracted into ethyl acetate; the organic layer is washed with clarified brine to remove residual activated carbonate below 0.3% as determined by evaporative light scattering detection. The isolated thiazole-carbonate intermediate is coupled in the subsequent step with a Val-Cit-PAB-OH linker at 1.0:1.03 stoichiometry in DMF containing 0.5% v/v diisopropylethylamine, and the conjugated linker-thiazole construct is isolated by preparative reversed-phase chromatography on a C18 column with a gradient of acetonitrile in ammonium acetate buffer (20 mM, pH 5.8). Because this material enters the conjugation suite for attachment to a monoclonal antibody through interchain cysteine residues, the trace levels of extractable elements are controlled to ≤1 ppm for palladium and copper per USP <232>/ICH Q3D. The regulatory framework invokes FDA 21 CFR Part 211 for finished pharmaceuticals in conjugation with the EMA Guideline on requirements for quality documentation concerning biological starting materials. The final ADC bulk drug substance typically achieves a drug-to-antibody ratio (DAR) of 3.8–4.2 measured by hydrophobic interaction chromatography, and is formulated as a lyophilized cake in 20 mL Type I borosilicate vials under a nitrogen headspace.

Conversion of the 2-amino-5-hydroxymethylthiazole backbone into a cationic azo chromophore for polyacrylonitrile fibers exploits the facility with which the aromatic primary amine undergoes diazotization. The free aminothiazole hydrochloride is suspended in a mixture of glacial acetic acid, propionic acid, and 85% phosphoric acid (3:1:1 v/v/v) and cooled to –3°C. A pre-cooled solution of sodium nitrite (1.02 molar equivalents, dissolved in the minimum quantity of water) is pumped below the liquid surface at a rate that maintains the internal temperature below 2°C and the exotherm slope shallower than 1.5°C/min, as monitored by a coaxial Pt100 probe. A positive starch-iodide test after 30 minutes confirms excess nitrous acid. This cold diazonium salt is then added to a well-stirred solution of N-ethyl-N-cyanoethylaniline (1.0 equivalent) in methanol at 0°C, adjusting the pH to 4.0–4.3 with sodium acetate trihydrate. The coupling is complete within 2 hours, and the precipitated dye is collected, washed with 10% sodium chloride solution, and dried in a fluid-bed dryer at 60°C to a moisture content below 2.0%. The finished product corresponds to C.I. Basic Yellow 28 analog (locally designated as Thiazole Yellow A-2C), possesses a λmax of 438 nm in methanol, and is supplied as a free-flowing powder with a mean particle diameter of 200–400 µm. Dyeing of high-bulk acrylic tow is performed in a Gaston County package dyeing machine at a liquor ratio of 1:15, using 1.5% o.w.f. dye with the addition of 10 g/L anhydrous sodium sulfate and 0.5 g/L acetic acid-sodium acetate buffer at pH 4.5. Exhaustion rates typically exceed 96% at 98°C over 45 minutes. ZDHC MRSL 2.0 conformity and ECO PASSPORT by OEKO-TEX are the mandated toxicological and ecological credentials for this dye class, with batchwise certification conducted by ISO 105-J01 for color difference evaluation and EN 14362-1 for free aromatic amine content.